Warfield Weekly Update
Nov. 14, 2008
SDSS Quick Links >   Home  |  Join SDSS  |  National Certification for Skin Care Professionals   |  Bookstore  |  SDSS Corporate Members
Free Issue of the PCI Journal  |  7th Annual Meeting of the SDSS

New Viral Vaccines for Dermatologic Disease

By Cristine Urman, M.D. & Alice Gottlieb, M.D., PhD
Published in J Am Acad Dermatol 2008, 58;3:361370

Two new viral vaccines have been recently approved by the United States Food and Drug Administration (FDA). The human papillomavirus (HPV) vaccine has been approved to reduce infection with HPV types that cause cervical cancer and genital warts. The second vaccine, herpes zoster (HZ) vaccine has been developed to prevent shingles and its complications.

Learning Objective

The goal of this study was to familiarize the skin care specialist with the HPV and HZ viruses and to consider HPV and HZ vaccines for prevention of disease.

Human Papillomavirus

Human papillomavirus (HPV) is a double-stranded DNA virus that infects human epithelial tissues. Although more than 100 types of HPV have been identified, types 16 and 18 cause about 70% of cervical cancers and types 6 and 11 cause more than 90% of genital warts. The new HPV vaccine has been tested in clinical trials and showed promising results for the four identified types of HPV discussed above. The combined incidence of persistent HPV 6, 11, 16, or 18 at the end of the study was decreased by 90%.

HPV Vaccine

On June 8, 2006, the FDA approved the vaccine for use in females 9 to 26 years of age for the prevention of cervical, vaginal, and vulvar cancers, precancers and genital warts.

Herpes Zoster

Shingles is caused by the reactivation of the latent varicella virus (chickenpox). It is a double-stranded DNA virus and is a member of the herpes family. Primary infection with the virus causes chickenpox in children. Shingles or herpes zoster (HZ) is a reactivation of the same virus in the older population as the natural immune system begins to decline with age or in immunosuppressed individuals. HZ affects between 600,000 and 900,000 people annually. The cumulative lifetime risk of HZ in the entire population is between 10% and 20%.

Current Treatments

Current treatments for HZ are costly and do not prevent the symptoms or the common complication of postherpetic neuralgia. As a result, prevention of HZ reactivation with a vaccine has been sought. The end of the study showed that HZ was decreased 61.1% and the incidence of postherpetic neuralgia was reduced 66.5%. However, in the case of HZ further studies are needed to provide data on the cost-effectiveness as hundreds of people will need to be vaccinated to prevent a single case of HZ or postherpetic neuralgia.

Reprint requests: Dr. Christine Urman, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02110.


Ben Maitland, Director of Advertising Sales

Download Media Kit

To contribute news to the Warfield Weekly Update, contact Frank Humada, Content Editor, 972.402.7089.

Recent Issues

 RSS Feed

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063